{"name":"UNICANCER","slug":"unicancer","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":15,"colorKey":"oncology","drugs":[{"name":"AC regimen","genericName":"AC regimen","slug":"ac-regimen","indication":"Breast cancer (early-stage and metastatic)","status":"phase_3"},{"name":"177Lu-PMSA-617","genericName":"177Lu-PMSA-617","slug":"177lu-pmsa-617","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression","status":"phase_3"},{"name":"5-fluoro-uracil","genericName":"5-fluoro-uracil","slug":"5-fluoro-uracil","indication":"Colorectal cancer","status":"marketed"},{"name":"AMG102","genericName":"AMG102","slug":"amg102","indication":"Metastatic colorectal cancer","status":"phase_2"},{"name":"Anti-aromatase inhibitor","genericName":"Anti-aromatase inhibitor","slug":"anti-aromatase-inhibitor","indication":"Breast cancer","status":"phase_2"},{"name":"CHEMOTHERAPY then HORMONOTHERAPY","genericName":"CHEMOTHERAPY then HORMONOTHERAPY","slug":"chemotherapy-then-hormonotherapy","indication":"Hormone receptor-positive breast cancer (likely primary indication based on UNICANCER focus)","status":"phase_3"},{"name":"Capecitabine tablets","genericName":"Capecitabine tablets","slug":"capecitabine-tablets","indication":"Metastatic colorectal cancer","status":"marketed"},{"name":"DNA intercalators","genericName":"DNA intercalators","slug":"dna-intercalators","indication":"Various solid tumors and hematologic malignancies (specific indications under phase 2 evaluation by UNICANCER)","status":"phase_2"},{"name":"FOLFOX4s","genericName":"FOLFOX4s","slug":"folfox4s","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Fulvestrant Prefilled Syringe","genericName":"Fulvestrant Prefilled Syringe","slug":"fulvestrant-prefilled-syringe","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"HIPEC","genericName":"HIPEC","slug":"hipec","indication":"Peritoneal carcinomatosis from colorectal cancer","status":"phase_3"},{"name":"L-folinic","genericName":"L-folinic","slug":"l-folinic","indication":"Colorectal cancer (adjuvant and metastatic, in combination with 5-fluorouracil)","status":"phase_3"},{"name":"Nivolumab Injection","genericName":"Nivolumab Injection","slug":"nivolumab-injection","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Reduced dose intensity of IO","genericName":"Reduced dose intensity of IO","slug":"reduced-dose-intensity-of-io","indication":"Cancer treatment optimization via dose-reduced immunotherapy regimens (specific tumor types under investigation in UNICANCER phase 3 trial)","status":"phase_3"},{"name":"mFolfox6 or capecitabine","genericName":"mFolfox6 or capecitabine","slug":"mfolfox6-or-capecitabine","indication":"Adjuvant treatment of stage III colon cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Fluorouracile","genericName":"Fluorouracile","slug":"fluorouracile","indication":"Other","status":"discontinued"},{"name":"Folinic Acid","genericName":"Folinic Acid","slug":"folinic-acid","indication":"Other","status":"marketed"},{"name":"IV Chemotherapy (Regimen 1)","genericName":"IV Chemotherapy (Regimen 1)","slug":"iv-chemotherapy-regimen-1","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"AC regimen","genericName":"AC regimen","slug":"ac-regimen","phase":"phase_3","mechanism":"AC regimen is a chemotherapy combination of doxorubicin (Adriamycin) and cyclophosphamide that damages cancer cell DNA to inhibit tumor growth.","indications":["Breast cancer (early-stage and metastatic)","Lymphomas","Sarcomas","Other solid tumors (as part of combination regimens)"],"catalyst":""},{"name":"177Lu-PMSA-617","genericName":"177Lu-PMSA-617","slug":"177lu-pmsa-617","phase":"phase_3","mechanism":"177Lu-PMSA-617 is a radioligand therapy that delivers lutetium-177 radiation directly to prostate cancer cells expressing PSMA, causing targeted cell death.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"],"catalyst":""},{"name":"5-fluoro-uracil","genericName":"5-fluoro-uracil","slug":"5-fluoro-uracil","phase":"marketed","mechanism":"5-fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cell death.","indications":["Colorectal cancer","Gastric cancer","Breast cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"AMG102","genericName":"AMG102","slug":"amg102","phase":"phase_2","mechanism":"AMG102 is a recombinant human tumor necrosis factor (TNF) receptor fusion protein.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"Anti-aromatase inhibitor","genericName":"Anti-aromatase inhibitor","slug":"anti-aromatase-inhibitor","phase":"phase_2","mechanism":"Inhibits the enzyme aromatase","indications":["Breast cancer"],"catalyst":""},{"name":"CHEMOTHERAPY then HORMONOTHERAPY","genericName":"CHEMOTHERAPY then HORMONOTHERAPY","slug":"chemotherapy-then-hormonotherapy","phase":"phase_3","mechanism":"A sequential treatment regimen that first uses chemotherapy to reduce tumor burden, followed by hormone therapy to suppress hormone-dependent cancer cell growth.","indications":["Hormone receptor-positive breast cancer (likely primary indication based on UNICANCER focus)"],"catalyst":""},{"name":"Capecitabine tablets","genericName":"Capecitabine tablets","slug":"capecitabine-tablets","phase":"marketed","mechanism":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.","indications":["Metastatic colorectal cancer","Metastatic breast cancer","Gastric cancer","Pancreatic cancer"],"catalyst":""},{"name":"DNA intercalators","genericName":"DNA intercalators","slug":"dna-intercalators","phase":"phase_2","mechanism":"DNA intercalators insert themselves between DNA base pairs to disrupt DNA replication and transcription, leading to cancer cell death.","indications":["Various solid tumors and hematologic malignancies (specific indications under phase 2 evaluation by UNICANCER)"],"catalyst":""},{"name":"FOLFOX4s","genericName":"FOLFOX4s","slug":"folfox4s","phase":"phase_3","mechanism":"FOLFOX4s is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","indications":["Metastatic colorectal cancer","Adjuvant treatment of stage III colorectal cancer"],"catalyst":""},{"name":"Fluorouracile","genericName":"Fluorouracile","slug":"fluorouracile","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Folinic Acid","genericName":"Folinic Acid","slug":"folinic-acid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fulvestrant Prefilled Syringe","genericName":"Fulvestrant Prefilled Syringe","slug":"fulvestrant-prefilled-syringe","phase":"phase_3","mechanism":"Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors in hormone receptor-positive breast cancer cells.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","Hormone receptor-positive breast cancer in postmenopausal women (first-line or subsequent lines of endocrine therapy)"],"catalyst":""},{"name":"HIPEC","genericName":"HIPEC","slug":"hipec","phase":"phase_3","mechanism":"HIPEC is a hyperthermic intraperitoneal chemotherapy delivery system that circulates heated chemotherapy drugs directly into the abdominal cavity during surgery to treat peritoneal cancers.","indications":["Peritoneal carcinomatosis from colorectal cancer","Peritoneal carcinomatosis from ovarian cancer","Peritoneal mesothelioma"],"catalyst":""},{"name":"IV Chemotherapy (Regimen 1)","genericName":"IV Chemotherapy (Regimen 1)","slug":"iv-chemotherapy-regimen-1","phase":"phase_3","mechanism":"IV Chemotherapy Regimen 1 is a combination chemotherapy treatment that kills rapidly dividing cancer cells through DNA damage and cell cycle disruption.","indications":[],"catalyst":""},{"name":"L-folinic","genericName":"L-folinic","slug":"l-folinic","phase":"phase_3","mechanism":"L-folinic acid (leucovorin) is a reduced form of folic acid that enhances the activity of fluorouracil-based chemotherapy by stabilizing the ternary complex between fluorodeoxymonophosphate, thymidylate synthase, and the cofactor.","indications":["Colorectal cancer (adjuvant and metastatic, in combination with 5-fluorouracil)","Gastric cancer","Breast cancer (in combination with fluoropyrimidines)"],"catalyst":""},{"name":"Nivolumab Injection","genericName":"Nivolumab Injection","slug":"nivolumab-injection","phase":"phase_3","mechanism":"Nivolumab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic melanoma","Non-small cell lung cancer","Renal cell carcinoma","Classical Hodgkin lymphoma","Squamous cell carcinoma of the head and neck"],"catalyst":""},{"name":"Reduced dose intensity of IO","genericName":"Reduced dose intensity of IO","slug":"reduced-dose-intensity-of-io","phase":"phase_3","mechanism":"Reduced dose intensity of immunotherapy (IO) aims to maintain anti-tumor efficacy while decreasing treatment-related toxicity through lower or less frequent dosing schedules.","indications":["Cancer treatment optimization via dose-reduced immunotherapy regimens (specific tumor types under investigation in UNICANCER phase 3 trial)"],"catalyst":""},{"name":"mFolfox6 or capecitabine","genericName":"mFolfox6 or capecitabine","slug":"mfolfox6-or-capecitabine","phase":"phase_3","mechanism":"capecitabine is a prodrug that is converted into 5-fluorouracil, which is then incorporated into DNA and RNA, interfering with cancer cell replication.","indications":["Adjuvant treatment of stage III colon cancer","Advanced colorectal cancer","Metastatic breast cancer","Metastatic colorectal cancer","Metastatic gastric cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":18,"phaseCounts":{"phase_3":11,"marketed":3,"phase_2":3,"discontinued":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}